Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France.

Authors:
Address: INSERM, CESP Centre for Research in Epidemiology and Population Health, U1018, Nutrition, Hormones and Women's Health Team, Villejuif, France.
Journal:

Publication:

abstract

PURPOSE:

To Estimate the number of deaths from valvular insufficiency caused by the use of the fenfluramine-derivative benfluorex during the period 1976-2009 in France.

METHODS:

Our calculation was based on (i) the exposure level to benfluorex in the French population, derived from sales figures for the period 1976-2009 and from the main characteristics of benfluorex use provided by the French health products safety agency; (ii) the relative risk of hospitalization for valvular insufficiency among exposed compared with unexposed individuals with diabetes, originating from a cohort study based on a French medico-administrative database, with benfluorex exposure assessed in 2006; (iii) the incidence of hospitalization for valvular insufficiency among exposed individuals, originating from the same database; and (iv) the mortality associated with valvular heart disease.

RESULTS:

In France, use of benfluorex during the period 1976-2009 is likely to be responsible for around 3100 hospitalizations and 1300 deaths due to valvular insufficiency. These figures may be underestimations.

CONCLUSIONS:

The grave consequences benfluorex use have had for many people lend support to the public investigation, which has been set to understand the reasons that have contributed to the delay in withdrawing benfluorex from the French market. Copyright © 2012 John Wiley & Sons, Ltd.

Related Articles
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program. Rep Carcinog Backgr Doc. 2010 Jan; (10-5981):i-512.
Review [Benfluorex and valvular heart disease].
Presse Med. 2011
Review [Benfluorex and valvular heart disease].
Tribouilloy C, Jeu A, Maréchaux S, Jobic Y, Rusinaru D, Andréjak M. Presse Med. 2011 Nov; 40(11):1008-16. Epub 2011 Oct 5.
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.
Pharmacoepidemiol Drug Saf. 2010
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.
Weill A, Païta M, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H. Pharmacoepidemiol Drug Saf. 2010 Dec; 19(12):1256-62. Epub 2010 Oct 13.
Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease.
Eur J Echocardiogr. 2011
Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease.
Boudes A, Lavoute C, Avierinos JF, Le Dolley Y, Villacampa C, Salem A, Loundou AD, Michel N, Renard S, Habib G. Eur J Echocardiogr. 2011 Sep; 12(9):688-95. Epub 2011 Aug 2.
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Encephale. 2005
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, et al. Encephale. 2005 Mar-Apr; 31(2):235-46.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.